Investigating the effectiveness of L-arginine in reducing duration of hospitalization and pain intensity of children with sickle cell disease compared to placebo.
Phase 3
- Conditions
- Sickle cell disease.Other sickle-cell disorders with crisisD57.81
- Registration Number
- IRCT20170112031891N2
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Patients affected by sickle cell disease
Age 3 to 20 years
Exclusion Criteria
liver failure
Renal failure
Under 5 grams of hemoglobin per deciliter
Patients in need of immediate infusion of blood
Pregnancy
History of hospitalization more than 10 times in the hospital
A history of opiate dependence
Sensitivity to arginine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pain. Timepoint: A week. Method of measurement: Based on Visual Analogue Scale and Faces Pain.;Time of Hospitalization. Timepoint: The duration of treatment. Method of measurement: The duration of Hospitalization.
- Secondary Outcome Measures
Name Time Method Pharmaceutical allergy. Timepoint: The duration of treatment. Method of measurement: Clinical observation.